Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Outsmarting HIV With Vaccine Antigens Made to Order

July 1, 2015 10:24 am | by Robin Smith, Duke University | News | Comments

AIDS vaccine researchers may be one step closer to outwitting HIV, thanks to designer antibodies and antigens made to order at Duke. Read more...

TOPICS:

Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin

July 1, 2015 10:17 am | News | Comments

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to its fully human monoclonal antibody Aerucin for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Read more...

TOPICS:

Avian Flu: $1.35M Grant Funds Bid to Better Predict Deadly Outbreaks

July 1, 2015 10:10 am | by University of Virginia Health System | News | Comments

An international research team led by Lukas Tamm of the University of Virginia School of Medicine will receive $1.35 million from the Human Frontier Science Program Organization to better understand how the influenza virus passes from birds to humans. Read more...

TOPICS:
Advertisement

Oxycontin Maker Bows Out of Meeting on Harder-to-Abuse Drug

July 1, 2015 10:02 am | by Matthew Perrone, AP Health Writer - Associated Press | News | Comments

The makers of the potent painkiller OxyContin have pulled out of a federal meeting to review the company's harder-to-abuse version of the much-debated drug. Read more...

TOPICS:

Forgetfulness and Errors Can Signal Alzheimer’s Decades Before Diagnosis

July 1, 2015 9:32 am | by Seth Augenstein, Digital Reporter | News | Comments

Mistakes on memory and thought tests may give an indication of the future onset of Alzheimer’s, up to 18 years before diagnosis, according to a new study. Read more...

TOPICS:

How Removing a Protein Slows Blood Vessel Growth in Tumors

July 1, 2015 8:43 am | by University of Leeds | News | Comments

Scientists have discovered a new protein which triggers the growth of blood vessels in breast cancer tumors which have spread to the brain. Read more...

TOPICS:

Oramed Enrolls First Patient in its Phase 2B Oral Insulin Study

July 1, 2015 8:36 am | News | Comments

This U.S. based study will be performed under the active Investigational New Drug application on file with the U.S. Food and Drug Administration. Read more...

TOPICS:

Liberia Quarantines an Area Where New Ebola Case Appeared

July 1, 2015 8:31 am | by Jonathan Paye-Layleh, Associated Press | News | Comments

The World Health Organization declared Liberia Ebola-free on May 9, after it went 42 days without a new case. Read more...

TOPICS:
Advertisement

Research Reveals New Insights into Key Antibiotic Target in Fight Against TB

July 1, 2015 8:30 am | by University of Sussex | News | Comments

While TB is curable, antibiotic resistance is on the rise and so a major challenge for scientists is to continually develop new drugs to treat the disease. Read more...

TOPICS:

BiondVax Announces Positive Preliminary Phase 2 Results for Universal Flu Vaccine

July 1, 2015 8:29 am | News | Comments

These results support BiondVax’s claim that M-001 provides a broaden and improved coverage against multiple influenza type A and B virus strains. Read more...

TOPICS:

Novartis to Try Novel Pricing Strategy for Heart Failure Drug

July 1, 2015 8:27 am | by Ryan Bushey, Associate Editor | Articles | Comments

The company is treading carefully in establishing the exact cost per pill. Read more...

TOPICS:

The Leukemia & Lymphoma Society Accelerates Payment Linked to Phase 3 AML Study

June 30, 2015 12:24 pm | by The Leukemia & Lymphoma Society | News | Comments

Celator Pharmaceuticals, Inc. today announced that The Leukemia & Lymphoma Society (LLS) is accelerating a portion of the final payment linked to the Phase 3 study of CPX-351 (cytarabine:daunorubicin) liposome injection, Celator's lead product candidate, for the treatment of patients with high-risk (secondary) acute myeloid leukemia (AML). Read more...

TOPICS:

National Study Finds Life-Threatening Barriers in Access to Breakthrough Drugs

June 30, 2015 12:16 pm | by Lifespan | News | Comments

Most states violate federal Medicaid law because they deny coverage for sofosbuvir, a new and highly effective treatment to cure hepatitis C, according to Lynn E. Taylor, M.D., director of The Miriam Hospital's HIV/Viral Hepatitis Coinfection Program.  Read more...

TOPICS:

Stiolto Respimat Now Available in the U.S. for COPD Treatment

June 30, 2015 11:52 am | News | Comments

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States. Read more...                      

TOPICS:

Treatment With PI3K Inhibitors May Cause Cancers to Become Aggressive, Metastatic

June 30, 2015 11:43 am | by The Wistar Institute | News | Comments

The enzyme phosphatidylinositol-3 kinase (PI3K) appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target, with many PI3K-inhibiting drugs currently in various stages of clinical development.  Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading